Update to 'Benefit Criteria to Change for Neurostimulators and Neuromuscular Stimulators Effective October 1, 2014'

Information posted November 7, 2014

This is an update to an article titled "Benefit Criteria to Change for Neurostimulators and Neuromuscular Stimulators Effective October 1, 2014," which was published on this website on August 15, 2014.

The article did not include the following information:

Documentation submitted for permanent implantation and purchase of the dorsal column stimulation (DCN) device must also demonstrate that:

- Other treatment modalities, including pharmacological, surgical, physical, and/or psychological therapies, have been tried and were shown to be unsatisfactory, unsuitable, or contraindicated for the client.
- The client has undergone careful screening, evaluation, and diagnosis by a multidisciplinary team prior to implantation.
- The facilities, equipment, and professional and support personnel required for the proper diagnosis, treatment, training, and follow-up of the client are available.
- There has been demonstrated evidence of pain relief during a trial period of DCN with a temporarily implanted electrode or electrodes preceding the permanent implantation. The trial period must be a minimum of 30 days in duration.

***Note**: The trial period including device and supplies is considered part of the DCN procedure and will not be separately reimbursed.*

Providers may request prior authorization for clients without one of the medical conditions listed in the current *CSHCN Services Program Provider Manual*, Section 27.2.1, "Dorsal Column Neurostimulation (DCN)." The provider must submit documentation of medical necessity with the request, which will be reviewed by the Department of State Health Services (DSHS)-Children with Special Health Care Needs (CSHCN) Services Program Medical Director or a designee.

For more information, call the TMHP-CSHCN Services Program Contact Center at 1-800-568-2413.